65 results
424B5
ITCI
Intra-Cellular Therapies Inc
18 Apr 24
Prospectus supplement for primary offering
5:23pm
, patients, or the medical community, thereby limiting our potential to generate revenues, which will undermine our future growth prospects.
We rely
424B5
ITCI
Intra-Cellular Therapies Inc
16 Apr 24
Prospectus supplement for primary offering
4:37pm
potential products.
CAPLYTA and our product candidates, if approved, may not gain acceptance among physicians, patients, or the medical community
424B5
nizst6n7hzhugwxjl
5 Jan 22
Prospectus supplement for primary offering
4:51pm
424B5
fh64mnhj
3 Jan 22
Prospectus supplement for primary offering
5:30pm
PRE 14A
hsuqh9mpb578 9bio
19 Apr 21
Preliminary proxy
5:28pm